Free Trial

Bioventus (BVS) Competitors

Bioventus logo
$10.39 -0.02 (-0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$10.39 0.00 (0.00%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BVS vs. IRTC, WRBY, LIVN, ENOV, TMDX, NVCR, TNDM, LMAT, SLNO, and CNMD

Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include iRhythm Technologies (IRTC), Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), TransMedics Group (TMDX), NovoCure (NVCR), Tandem Diabetes Care (TNDM), LeMaitre Vascular (LMAT), Soleno Therapeutics (SLNO), and CONMED (CNMD). These companies are all part of the "medical equipment" industry.

Bioventus vs.

iRhythm Technologies (NASDAQ:IRTC) and Bioventus (NYSE:BVS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.

iRhythm Technologies has higher earnings, but lower revenue than Bioventus. iRhythm Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$492.68M7.14-$123.41M-$4.86-23.13
Bioventus$512.34M1.65-$156.23M-$0.61-17.03

iRhythm Technologies received 377 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 66.29% of users gave iRhythm Technologies an outperform vote while only 62.50% of users gave Bioventus an outperform vote.

CompanyUnderperformOutperform
iRhythm TechnologiesOutperform Votes
407
66.29%
Underperform Votes
207
33.71%
BioventusOutperform Votes
30
62.50%
Underperform Votes
18
37.50%

iRhythm Technologies currently has a consensus price target of $108.45, suggesting a potential downside of 3.52%. Bioventus has a consensus price target of $15.00, suggesting a potential upside of 44.37%. Given Bioventus' higher possible upside, analysts clearly believe Bioventus is more favorable than iRhythm Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82
Bioventus
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

62.9% of Bioventus shares are held by institutional investors. 0.7% of iRhythm Technologies shares are held by company insiders. Comparatively, 32.9% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, iRhythm Technologies had 3 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for iRhythm Technologies and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.76 beat iRhythm Technologies' score of 0.35 indicating that Bioventus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRhythm Technologies
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bioventus
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Bioventus has a net margin of -7.11% compared to iRhythm Technologies' net margin of -26.90%. Bioventus' return on equity of 15.61% beat iRhythm Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
iRhythm Technologies-26.90% -120.86% -17.96%
Bioventus -7.11%15.61%4.01%

iRhythm Technologies has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Summary

Bioventus beats iRhythm Technologies on 10 of the 18 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BVS vs. The Competition

MetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$843.15M$4.69B$5.77B$20.42B
Dividend YieldN/A47.50%5.25%3.67%
P/E Ratio-17.0325.9426.4445.96
Price / Sales1.6564.45455.0518.05
Price / Cash13.7050.3946.0620.33
Price / Book3.716.547.255.72
Net Income-$156.23M$89.44M$3.19B$1.00B
7 Day Performance-2.72%2.42%2.14%0.77%
1 Month Performance3.49%2.29%3.49%1.70%
1 Year Performance129.36%18.79%21.19%16.32%

Bioventus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BVS
Bioventus
3.5279 of 5 stars
$10.39
-0.2%
$15.00
+44.4%
+129.8%$843.15M$512.34M-17.031,200News Coverage
Positive News
High Trading Volume
IRTC
iRhythm Technologies
0.9399 of 5 stars
$109.50
-0.5%
$108.45
-1.0%
-1.8%$3.43B$492.68M-22.532,000
WRBY
Warby Parker
2.741 of 5 stars
$26.64
+1.0%
$21.77
-18.3%
+77.2%$2.71B$669.77M-98.683,491Positive News
LIVN
LivaNova
3.8048 of 5 stars
$48.51
+1.4%
$69.17
+42.6%
-4.4%$2.63B$1.15B115.502,900Upcoming Earnings
ENOV
Enovis
3.4793 of 5 stars
$44.45
+1.0%
$65.86
+48.1%
-26.0%$2.53B$1.71B-20.306,550Short Interest ↓
Positive News
TMDX
TransMedics Group
3.7169 of 5 stars
$70.24
-3.3%
$122.70
+74.7%
-19.7%$2.36B$241.62M74.72210News Coverage
NVCR
NovoCure
3.7979 of 5 stars
$21.65
-2.7%
$32.67
+50.9%
+39.3%$2.34B$509.34M-15.461,453
TNDM
Tandem Diabetes Care
4.1893 of 5 stars
$35.23
-2.4%
$53.81
+52.7%
+37.1%$2.31B$747.72M-18.252,400News Coverage
Positive News
LMAT
LeMaitre Vascular
2.2248 of 5 stars
$98.44
+0.5%
$94.57
-3.9%
+57.7%$2.21B$193.48M53.79490
SLNO
Soleno Therapeutics
4.4802 of 5 stars
$50.21
-0.3%
$71.20
+41.8%
+3.9%$2.16BN/A-15.1230
CNMD
CONMED
4.5326 of 5 stars
$67.41
+1.5%
$77.20
+14.5%
-22.2%$2.08B$1.31B15.904,000Short Interest ↑

Related Companies and Tools


This page (NYSE:BVS) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners